The Big Shift to FDA QMSR Final Rule: What Manufacturers Need to Know About the ISO 13485 Transition

How the 21 CFR Part 820 Amendment Harmonizes Global Quality Management Systems with the FDA QMSR Final Rule

The U.S. Food and Drug Administration has officially enacted one of the most significant modernizations to its medical device quality system regulations in decades. By issuing the highly anticipated FDA QMSR final rule (Quality Management System Regulation), the agency has substantially replaced the long-standing Quality System Regulation (QSR) framework. This massive regulatory pivot is achieved through the 21 CFR Part 820 amendment, which incorporates by reference the international consensus standard for medical device quality management systems, ISO 13485:2016. This shift marks a monumental step forward in global regulatory harmonization.

For decades, global medical device manufacturers had to maintain parallel compliance systems—one for international markets under ISO 13485, and an entirely separate system to fulfill the U.S. FDA QSR requirements. The 21 CFR Part 820 amendment eliminates this dual burden by establishing ISO 13485:2016 as the foundational pillar for U.S. quality management requirements. However, manufacturers must understand that compliance with the FDA QMSR final rule is not automatically achieved simply by holding an ISO certificate. The FDA has integrated targeted, supplemental requirements within the QMSR to ensure full alignment with the Federal Food, Drug, and Cosmetic Act (FD&C Act), specifically regarding record-keeping, labeling controls, and unique combination product regulations.

The transition period is officially complete, and the FDA has fully shifted its inspectional approach to the new QMSR framework. FDA investigators now evaluate quality system compliance through a highly risk-based lens, focusing on product-specific risks, safety histories, and organizational competency rather than just training logs. Companies that proactively managed their ISO 13485 transition and carefully mapped the FDA’s specific supplemental requirements are now finding themselves at a major competitive advantage, enjoying streamlined operations and unified global quality standards under the consolidated FDA QMSR final rule.

Source: https://www.fda.gov/medical-devices/quality-management-system-regulation-qmsr/quality-management-system-regulation-frequently-asked-questions